Effect of HPV Vaccination on Women Aged 25 Years

Cervical Cancer Clinical Trial

Official title:

Effective Surveillance and Impact of HPV Vaccination on Screening for Cervical Cancer in Tuscany

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02296255
• Other study ID #: F11J09000350002
• Secondary ID: 342/2009
• Status: Completed
• Phase: Phase 4
• First received: November 11, 2014
• Last updated: November 19, 2014
• Start date: April 2010
• Est. completion date: July 2013

Study information

• Verified date: November 2014
• Source: Cancer Prevention and Research Institute, Italy
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: National Institute of Health
• Study type: Interventional

Clinical Trial Summary

The purposes of this study are to evaluate the effectiveness of vaccination in 25-year old women at the time of their first access to cervical cancer screening, to understand the impact of vaccination on screening activity; to evaluate the immune response following vaccination; to study the dynamics of the infection after vaccination, including the possible change in the frequency of non-vaccine HPV types, to evaluate cytological abnormalities reductions in vaccinated women and to assess if HPV test in urine sample could be a useful non-invasive method to monitor HPV status in younger women.

Description:

The present trial, funded by Istituto Toscano Tumori, started in 2010 and was directed to all women aged 25 (birth cohorts 1985 and 1986), resident in the province of Florence and targeted by the screening program. After receiving approval from the Ethics Committee of the Local Health Unit of Florence, women were invited by invitation letter containing a clear description of the study. All women complying with the invitation were asked to fill in the informed consent document.

Women were randomized 1:2 in the Experimental Arm or in the Control Arm. At enrollment, women in the Experimental Arm, after collection of cervical samples (for Pap-test and HPV test), blood sample (for HPV antibody testing on serum before vaccination) and one first void urine sample (for HPV testing), received free vaccination with Cervarix® (vaccine against HPV 16 and 18, 3 doses scheduled). Women in the Control Arm received usual care, i.e. the collection of cervical sample for Pap test.

All women who signed the informed consent have been enrolled regardless of being sexually active or not. For virgo women cervical sample was not collected.

At the second round of screening (30 months since enrollment), women in both Arms were asked to collect cervical samples (for Pap-test and HPV test) while a new blood sample for HPV antibody testing was collected only in women enrolled in the Experimental Arm.

Women with normal cytology in Control Arm and women with HPV-negative result and normal cytology in Experimental Arm, received a recommendation by mail to repeat screening test after 3 years. Women with abnormal Pap test (Atypical Squamous Cells of Undetermined Significance or more severe, ASC-US+) were referred to immediate colposcopy at the Cancer Prevention and Research Insitute. Women with normal cytology and HPV positive were called after one year to repeat HPV test and Pap test. If HPV and Pap test were negative, women repeated both test after 30 months from enrolment. Otherwise if HPV test remained positive and/or cytology abnormalities were detected women were referred for colposcopy: if colposcopy didn't reveal high grade lesions (≤ CIN2) women repeated HPV and Pap test after 30 months from enrollment, if colposcopy revealed final histological diagnosis of CIN2+ lesions, women were recommended for an excisional treatment (both for study and control group).

The presence of high risk (HR) HPVs was evaluated by Hybrid Capture 2 (Qiagen, Gaithersburg, USA) using probe B for the detection of 12 high risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 (Group 1) and 1 "probably carcinogenic to humans" type HPV 68 (Group 2).

HPV genotyping was performed by INNO-LiPA Genotyping Extra that allows the identification of 28 different HPV types on L1 region on the HPV genome, it identifies all known HPV high-risk types (Group 1) 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59; "probably carcinogenic to humans" (Group 2A) HPV68; and all "possibly carcinogenic" HPV 26, 53, 66, 69, 70, 73, 82 (Group 2B) and "not classified as to its carcinogenicity to humans" (Group 3) (6, 11); and other HPV types: 40, 43, 44, 54, 71, 74.

HPV antibody testing was performed on an established and validated HPV serology method based on Luminex technology heparin coating of the beads and pseudovirions (PsVs) of 17 HPV types belonging to alpha species: 3, 6, 11, 16, 18, 31, 32 ,33, 35, 39, 45, 52, 56, 58, 59, 68, 73, and for four HPV types belonging to beta species: 5, 15, 38, 76.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 832
• Est. completion date: July 2013
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 25 Years to 25 Years

Eligibility

Inclusion Criteria:

• resident in Florence

• invited for the first time to the cervical cancer screening in Florence

• aged 25 years

Exclusion Criteria:

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Biological:
• Cervarix®, GlaxoSmithKline
3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline

Locations

Country	Name	City	State
Italy	Cancer Prevention and Research Institute, ISPO	Firenze	FI

Sponsors (3)

Lead Sponsor	Collaborator
Cancer Prevention and Research Institute, Italy	Istituto Toscano Tumori, University of Florence

Country where clinical trial is conducted

Italy, 

References & Publications (2)

Burroni E, Bonanni P, Sani C, Lastrucci V, Carozzi F; Hpv ScreeVacc Working Group, Iossa A, Andersson KL, Brandigi L, Di Pierro C, Confortini M, Levi M, Boccalini S, Indiani L, Sala A, Tanini T, Bechini A, Azzari C. Human papillomavirus prevalence in pair — View Citation

Levi M, Bonanni P, Burroni E, Bechini A, Boccalini S, Sani C, Bonaiuti R, Indiani L, Azzari C, Lippi F, Carozzi F; HPV Screevacc Working Group. Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tu — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of HR-HPV infections and number of infections due to HPV vaccine types in cervical sample in the Experimental arm and in No intervention arm		30 months	No
Primary	number of cytological abnormalities in the Experimental arm and in No intervention arm		30 months	No
Secondary	Number of subjects seropositive for HPV 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59, 68 at enrollment		enrollment	No
Secondary	Number of subjects seropositive for HPV16,18 31, 33, 35, 39, 45, 52, 56, 58, 59, 68 after vaccination		30 months	No
Secondary	Anti-HPV16,18 31, 33, 35, 39, 45, 52, 56, 58, 59, 68 Antibody Titers before vaccination	Titers are given as Mean Fluorescence Intensity Unit (MFI)	at enrollment	No
Secondary	Anti-HPV16,18 31, 33, 35, 39, 45, 52, 56, 58, 59, 68 Antibody Titers after vaccination	Titers are given as Mean Fluorescence Intensity Unit (MFI)	30 months	No
Secondary	Number of participants reporting Adverse Events	Adverse Events assessed include Local pain, Local swelling, Local pruritus, Local Erythema, Fever, and every adverse event reported day by day in a diary	within 14 days following any injection	Yes
Secondary	HPV identification in urine samples		at enrollment	No